Low Leverage And Balance-sheet FlexibilityModest reported debt and a low debt-to-equity ratio give the company financial flexibility to fund R&D cycles without large interest burdens. For a pre-commercial biotech, low leverage preserves ability to raise project financing or structure deals with partners over the next several quarters.

Partnership-focused Commercial StrategyA deliberate model of advancing proprietary candidates through early development and then partnering reduces the need for late-stage capital and outsources commercialization risk. This strategy can sustainably de-risk capital intensity and accelerate value realization via milestones and co-development.

Focused CNS/Alzheimer’s PipelineConcentrated expertise in CNS and Alzheimer’s targets aligns with a large unmet medical need and persistent structural demand. Specialization can improve trial design, partner interest, and licensing potential, supporting durable commercial optionality if clinical progress continues.

Bears Say

No Revenue And Widening Net LossesA sustained absence of revenue alongside growing annual losses means the company must rely on external funding or partner deals to continue operations. This structural reliance increases dilution and execution risk until a commercial product or material partnership is secured.

Negative Operating And Free Cash Flow (ongoing Burn)Consistent negative operating and free cash flows indicate the company is burning cash to fund R&D. Over 2–6 months this creates a durable funding imperative: limited runway forces prioritization of projects and increases probability of dilutive financing or hurried partnerships.

Material Equity Erosion Raises Funding VulnerabilityMarked decline in shareholders' equity reflects accumulated losses and reduces the company’s capital buffer. This structural weakening lowers non-dilutive financing options, heightens sensitivity to adverse outcomes, and makes future equity raises more dilutive and costly.

ALZCUR FAQ

What was AlzeCure Pharma AB’s price range in the past 12 months?

AlzeCure Pharma AB lowest stock price was kr1.43 and its highest was kr4.95 in the past 12 months.

What is AlzeCure Pharma AB’s market cap?

AlzeCure Pharma AB’s market cap is kr194.78M.

When is AlzeCure Pharma AB’s upcoming earnings report date?

AlzeCure Pharma AB’s upcoming earnings report date is May 05, 2026 which is in 44 days.

How were AlzeCure Pharma AB’s earnings last quarter?

AlzeCure Pharma AB released its earnings results on Feb 26, 2026. The company reported -kr0.154 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.154.

Is AlzeCure Pharma AB overvalued?

According to Wall Street analysts AlzeCure Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does AlzeCure Pharma AB pay dividends?

AlzeCure Pharma AB does not currently pay dividends.

What is AlzeCure Pharma AB’s EPS estimate?

AlzeCure Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does AlzeCure Pharma AB have?

AlzeCure Pharma AB has 114,914,450 shares outstanding.

What happened to AlzeCure Pharma AB’s price movement after its last earnings report?

AlzeCure Pharma AB reported an EPS of -kr0.154 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.188%.

Which hedge fund is a major shareholder of AlzeCure Pharma AB?

Currently, no hedge funds are holding shares in SE:ALZCUR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

AlzeCure Pharma AB

AlzeCure Pharma AB (ALZCUR) is a Swedish pharmaceutical company that focuses on developing innovative therapies for neurodegenerative diseases, with a particular emphasis on Alzheimer's disease and pain management. The company operates in the biotechnology sector, leveraging its expertise in neuroscience to advance its pipeline of drug candidates. AlzeCure's core products include a range of proprietary small molecule drugs that target key pathways involved in neurodegeneration.